Xeris Pharmaceuticals | XERS - Cost Of Sales


Xeris Pharmaceuticals reported $13.66M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Celltrion KRW 107.42B 295.44B Dec/2025
Cspc Pharmaceutical CNY 2.11B 173.58M Dec/2025
Deva Holding AS TRY 991.13M 182.81M Sep/2023
Divis Laboratories Ltd INR 12.39B 1.76B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Kangmei Pharma CNY 841.45M 271.27M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Laboratorios Farma EUR 186.09M 11.06M Dec/2023
Medical Developments International AUD 7.09M 4.91M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neuren Pharmaceuticals AUD 7.45M 6.56M Jun/2025
Organigram Holdings CAD 56.93M 20.53M Dec/2025
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pharma Mar EUR 3.66M 116K Mar/2026
Qiagen NV USD 217.43M 29.65M Dec/2025
Sartorius EUR 484.6M 46.6M Mar/2026
Sino Biopharmaceutical CNY 3.08B 589.65M Jun/2025
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Tilray USD 164.37M 8.41M Sep/2025
Zealand Pharma A/S 410K 5K Jun/2025
Zz Pientze Pharmaceu CNY 1.58B 245.15M Mar/2026